CMV Subunit Vaccine in Young Women at Risk
高危年轻女性的 CMV 亚单位疫苗
基本信息
- 批准号:7770604
- 负责人:
- 金额:$ 47.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-20 至 2010-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): This clinical trial will test the efficacy of cytomegalovirus (CMV) glycoprotein B (gB) vaccine (Aventis Pasteur) with MF59 adjuvant (Chiron Vaccines) to prevent maternal CMV infection, using a phase II, randomized, placebo controlled, double-blind clinical trial. Healthy young women are screened for antibody to CMV on the post-partum wards of 4 hospitals. Those who are seronegative are invited to participate in the clinical trial. Participants are enrolled and immunized (3 doses of vaccine, 0, 1 and 6 month schedule). Participants have follow-up visits every three months for three years after the third dose of vaccine in order to screen them for CMV infection, collect samples for immunogenicity studies, identify pregnancies and births, and collect safety information. All infants born to clinical trial participants are tested for congenital CMV infection by virus culture at birth. As of August 31, 2003, over 12,000 women had been screened for antibody to CMV, and 252 subjects enrolled. Twenty-eight CMV infections have occurred so far, a rate of 6.6% per year. There were 78 pregnancies among 66 trial participants, and 2 congenital CMV infections among 54 live births (3.7%). Important accomplishments in this trial to date include: enrolled around two-thirds of planned sample, developed a novel, accurate and inexpensive means of endpoint (CMV infection) detection for CMV vaccine clinical trials, recruited a study population with a CMV infection rate that allows us to accumulate the largest group of healthy asymptomatic young women with primary CMV infection ever studied, established use of immunologic and virologic assays that will allow us to learn a great deal from this trial whether or not vaccine is effective in preventing maternal infections.
Specific aims will test the ability of CMV gB/MF59 vaccine to prevent maternal infection, evaluate the rate of congenital CMV infection in offspring of trial participants, determine whether maternal CMV infection is associated with miscarriage, characterize the virologic and immunologic features of primary CMV infections, evaluate novel approaches to end-point identification in CMV vaccine clinical trials, define long-term immunogenicity of study vaccine (antibody to CMV gB, neutralizing antibody and cell mediated immune response) and compare rates of adverse events as well as local and systemic reactions in CMV gB/MF59 recipients to placebo recipients. Based on enrollment to date and the rate of CMV infection in trial participants, we expect to have 60 to 90 CMV infections in the study population and approximately 200 pregnancies. With planned enrollment and these event rates, the clinical trial will achieve the power needed to test efficacy for prevention of maternal infection and will provide a preliminary estimate of whether immunization affects rates of congenital CMV infection.
描述(由申请方提供):本临床试验将采用II期、随机、安慰剂对照、双盲临床试验,检测巨细胞病毒(CMV)糖蛋白B(gB)疫苗(Aventis Pasteur)与MF 59佐剂(Chiron Vaccines)预防母体CMV感染的有效性。在4家医院的产后病房对健康年轻妇女进行巨细胞病毒抗体筛查。邀请血清反应阴性者参加临床试验。参与者入组并免疫接种(3剂疫苗,0、1和6个月时间表)。参与者在第三剂疫苗接种后三年内每三个月进行一次随访,以筛查CMV感染,收集免疫原性研究样本,识别妊娠和分娩,并收集安全性信息。临床试验参与者出生的所有婴儿在出生时通过病毒培养检测先天性CMV感染。截至2003年8月31日,12 000多名妇女接受了巨细胞病毒抗体筛查,252名受试者参加了筛查。到目前为止,已经发生了28例CMV感染,每年的感染率为6.6%。66名试验参与者中有78例妊娠,54例活产婴儿中有2例先天性CMV感染(3.7%)。这一审判迄今取得的重要成就包括:招募了约三分之二的计划样本,开发了一种新颖、准确且廉价的终点方法(CMV感染)检测用于CMV疫苗临床试验,招募了一个研究人群,其CMV感染率使我们能够积累有史以来研究的最大一组患有原发性CMV感染的健康无症状年轻女性,免疫学和病毒学检测的建立使用将使我们能够从该试验中了解大量关于疫苗是否有效预防母体感染的信息。
具体目标将测试CMV gB/MF 59疫苗预防母体感染的能力,评估试验参与者后代的先天性CMV感染率,确定母体CMV感染是否与流产相关,表征原发性CMV感染的病毒学和免疫学特征,评估CMV疫苗临床试验中终点鉴定的新方法,定义研究疫苗的长期免疫原性(CMV gB抗体、中和抗体和细胞介导的免疫应答),并比较CMV gB/MF 59接种者与安慰剂接种者的不良事件发生率以及局部和全身反应。根据迄今为止的入组情况和试验参与者的CMV感染率,我们预计研究人群中将有60至90例CMV感染和约200例妊娠。有了计划的入组和这些事件发生率,临床试验将达到测试预防母体感染的有效性所需的把握度,并将提供免疫接种是否影响先天性CMV感染率的初步估计。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert Floyd Pass其他文献
Robert Floyd Pass的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert Floyd Pass', 18)}}的其他基金
PACTG P1026S PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS IN PREGNANCY
PACTG P1026S 妊娠期抗逆转录病毒药物的药代动力学特性
- 批准号:
7603188 - 财政年份:2007
- 资助金额:
$ 47.57万 - 项目类别:
RECOMBINANT CMV GB VACCINE IN POST-PARTUM WOMEN
用于产后妇女的重组 CMV GB 疫苗
- 批准号:
7603165 - 财政年份:2007
- 资助金额:
$ 47.57万 - 项目类别:
PACTG P1026S PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS IN PREGNANCY
PACTG P1026S 妊娠期抗逆转录病毒药物的药代动力学特性
- 批准号:
7380434 - 财政年份:2006
- 资助金额:
$ 47.57万 - 项目类别:
RECOMBINANT CMV GB VACCINE IN POST-PARTUM WOMEN
用于产后妇女的重组 CMV GB 疫苗
- 批准号:
7380398 - 财政年份:2006
- 资助金额:
$ 47.57万 - 项目类别:
OBSERVATIONAL STUDY OF PRIMARY CMV INFECTION IN YOUNG WOMEN
年轻女性原发性巨细胞病毒感染的观察性研究
- 批准号:
7198568 - 财政年份:2005
- 资助金额:
$ 47.57万 - 项目类别:
RECOMBINANT CMV GB VACCINE IN POSTPARTUM WOMEN
用于产后妇女的重组 CMV GB 疫苗
- 批准号:
7198520 - 财政年份:2005
- 资助金额:
$ 47.57万 - 项目类别:
PACTG P 1020A VERSION 20 PHASE I/II, OPEN-LABEL, PHARMACOKINETIC AND SAFETY STU
PACTG P 1020A 版本 20 I/II 期、开放标签、药代动力学和安全性 STU
- 批准号:
7198552 - 财政年份:2005
- 资助金额:
$ 47.57万 - 项目类别:
相似国自然基金
The Heterogenous Impact of Monetary Policy on Firms' Risk and Fundamentals
- 批准号:
- 批准年份:2024
- 资助金额:万元
- 项目类别:外国学者研究基金项目
基于移动健康技术干预动脉粥样硬化性心血管疾病高危人群的随机对照现场试验:The ASCVD Risk Intervention Trial
- 批准号:81973152
- 批准年份:2019
- 资助金额:54.0 万元
- 项目类别:面上项目
基于时间序列间分位相依性(quantile dependence)的风险值(Value-at-Risk)预测模型研究
- 批准号:71903144
- 批准年份:2019
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
RISK通路在胃泌素介导的心脏缺血再灌注损伤保护中的作用研究
- 批准号:81800239
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
异氟烷基于TLR4/RISK/NF-κB调控糖尿病缺血性脑卒中后NLRP3炎症小体形成的机制研究
- 批准号:81771232
- 批准年份:2017
- 资助金额:54.0 万元
- 项目类别:面上项目
Notch1与RISK/SAFE/HIF-1α信号通路整合在I-postC保护中的作用及其机制
- 批准号:81260024
- 批准年份:2012
- 资助金额:50.0 万元
- 项目类别:地区科学基金项目
相似海外基金
The role of youth voluntary actions in Disaster Risk Reduction in the Ganges Brahmaputra and Meghna (GBM) delta
青年志愿行动在雅鲁藏布江和梅格纳河三角洲减少灾害风险中的作用
- 批准号:
2593674 - 财政年份:2025
- 资助金额:
$ 47.57万 - 项目类别:
Studentship
Multiscale Approaches And Scalability Within Climate Change-heritage Risk Assessments
气候变化遗产风险评估中的多尺度方法和可扩展性
- 批准号:
AH/Z000084/1 - 财政年份:2024
- 资助金额:
$ 47.57万 - 项目类别:
Research Grant
Examining the Effect of Childhood Individual and Contextual Risk Factors on Violence Use and Experience at Early Adulthood (18-21 years)
检查童年个体和背景风险因素对成年早期(18-21 岁)暴力使用和经历的影响
- 批准号:
2901103 - 财政年份:2024
- 资助金额:
$ 47.57万 - 项目类别:
Studentship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 47.57万 - 项目类别:
Fellowship
NSF PRFB FY 2023: Considering evolutionary responses to temperature variability when predicting risk to climate change and disease in amphibians
NSF PRFB 2023 财年:在预测气候变化和两栖动物疾病风险时考虑对温度变化的进化反应
- 批准号:
2305659 - 财政年份:2024
- 资助金额:
$ 47.57万 - 项目类别:
Fellowship Award
Investigation of crosstalk between Fanconi Anemia pathway and ATM for novel therapeutic strategies of chemoresistant ALT-positive high-risk neuroblastoma
范可尼贫血通路与 ATM 之间的串扰研究,用于化疗耐药 ALT 阳性高危神经母细胞瘤的新治疗策略
- 批准号:
24K10442 - 财政年份:2024
- 资助金额:
$ 47.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Uncovering Mechanisms of Racial Inequalities in ADRD: Psychosocial Risk and Resilience Factors for White Matter Integrity
揭示 ADRD 中种族不平等的机制:心理社会风险和白质完整性的弹性因素
- 批准号:
10676358 - 财政年份:2024
- 资助金额:
$ 47.57万 - 项目类别:
I-Corps: Non-Invasive Software Tool for Risk Assessment of Intracranial Aneurysms (IA)
I-Corps:用于颅内动脉瘤 (IA) 风险评估的非侵入性软件工具
- 批准号:
2402381 - 财政年份:2024
- 资助金额:
$ 47.57万 - 项目类别:
Standard Grant
I-Corps: Translation Potential of a Machine Learning Risk Stratification Tool for Venous Thromboembolism
I-Corps:机器学习风险分层工具对静脉血栓栓塞的转化潜力
- 批准号:
2420417 - 财政年份:2024
- 资助金额:
$ 47.57万 - 项目类别:
Standard Grant